# Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

> **NCT07152288** · PHASE1 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** HSK39297 tablets
- **DRUG:** HSK39297 tablets
- **DRUG:** HSK39297 tablets

## Key facts

- **NCT ID:** NCT07152288
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2025-09
- **Final completion:** 2025-11
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152288, "Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07152288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*